Effects of a combined treatment with Glucomannan and Garcinia cambogia on patients with obesity

Combined treatment of Garcinia cambogia and Glucomannan reduce weight, change body composition and ameliorate lipid and glucose blood profiles of people with overweight or obesity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN48289853

Enrollment

135

Registered

2018-01-17

Start date

2015-01-08

Completion date

Unknown

Last updated

2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity/overweight Nutritional, Metabolic, Endocrine Obesity/overweight

Interventions

Participants have a balanced diet (Mediterranean diet), regular meals and intake of plenty of water. Standardised extracts of Garciania cambogia (52.4% Hydroxycitric acid) and Amorphophallus konjac (9

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Males and females 2. Aged 18 years old 3. Have an BMI>25 ;Inclusion criteria: 1. Males and females 2. Aged 18 years old 3. Have an BMI>25

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation 2. Gastroplasty or gastrointestinal weight-reducing surgery 3. Stopped smoking during the past 6 months 4. Kidney disease 5. History of recurrent kidney stones 6. Liver dysfunction 7. Untreated high blood pressure 8. History or symptoms of gallstones 9. Cancer 10. History of endocrine disorders (particularly hypothyroidism) 11. History of bulimia and/or laxative abuse 12. Mental disorders with impaired independence 13. History of alcohol or other drug abuse;Exclusion criteria: 1. Pregnancy or lactation 2. Gastroplasty or gastrointestinal weight-reducing surgery 3. Stopped smoking during the past 6 months 4. Kidney disease 5. History of recurrent kidney stones 6. Liver dysfunction 7. Untreated high blood pressure 8. History or symptoms of gallstones 9. Cancer 10. History of endocrine disorders (particularly hypothyroidism) 11. History of bulimia and/or laxative abuse 12. Mental disorders with impaired independence 13. History of alcohol or other drug abuse

Design outcomes

Primary

Measure	Time frame
1. Weight is measured using digital balance (HD-305 TanitaTM) to the nearest 0.1 kg at baseline, three and six months of treatment 2. Fat mass is measured using a BioScan Spectrum operating at 50 KHz at baseline, three and six months of treatment 3. Visceral Fat mass is measured using the BioScan Spectrum operating at 50 KHz at baseline, three and six months of treatment;1. Weight is measured using digital balance (HD-305 TanitaTM) to the nearest 0.1 kg at baseline, three and six months of treatment 2. Fat mass is measured using a BioScan Spectrum operating at 50 KHz at baseline, three and six months of treatment 3. Visceral Fat mass is measured using the BioScan Spectrum operating at 50 KHz at baseline, three and six months of treatment	—

Measure

Time frame

1. Weight is measured using digital balance (HD-305 TanitaTM) to the nearest 0.1 kg at baseline, three and six months of treatment 2. Fat mass is measured using a BioScan Spectrum operating at 50 KHz at baseline, three and six months of treatment 3. Visceral Fat mass is measured using the BioScan Spectrum operating at 50 KHz at baseline, three and six months of treatment;1. Weight is measured using digital balance (HD-305 TanitaTM) to the nearest 0.1 kg at baseline, three and six months of treatment 2. Fat mass is measured using a BioScan Spectrum operating at 50 KHz at baseline, three and six months of treatment 3. Visceral Fat mass is measured using the BioScan Spectrum operating at 50 KHz at baseline, three and six months of treatment

—

Secondary

Measure	Time frame
1. Glucose (mg/dl) is measured from blood samples using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment 2. Tryglerides (mg/dl) is measured from blood samples using using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment 3. Cholesterol (mg/dl) is measured from blood samples using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment;1. Glucose (mg/dl) is measured from blood samples using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment 2. Tryglerides (mg/dl) is measured from blood samples using using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment 3. Cholesterol (mg/dl) is measured from blood samples using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment	—

Measure

Time frame

1. Glucose (mg/dl) is measured from blood samples using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment 2. Tryglerides (mg/dl) is measured from blood samples using using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment 3. Cholesterol (mg/dl) is measured from blood samples using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment;1. Glucose (mg/dl) is measured from blood samples using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment 2. Tryglerides (mg/dl) is measured from blood samples using using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment 3. Cholesterol (mg/dl) is measured from blood samples using a colorimetric enzyme assay method (CEPA® kits – MBiolog Diagnósticos Ltda.) at baseline, three and six months of treatment

—

Countries

Spain

Contacts

Public Contact; ;

;

;;

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026